Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HR negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	QL1209 (pertuzumab biosimilar) Sensitive: B - Late Trials QL1209 (pertuzumab biosimilar) Sensitive : B	QL1209 (pertuzumab biosimilar) Sensitive: B - Late Trials QL1209 (pertuzumab biosimilar) Sensitive : B
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria carboplatin + paclitaxel Sensitive : C2	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria carboplatin + paclitaxel Sensitive : C2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	tegafur/uracil Sensitive: C3 – Early Trials tegafur / uracil Sensitive : C3	tegafur/uracil Sensitive: C3 – Early Trials tegafur / uracil Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	pertuzumab Sensitive: C3 – Early Trials pertuzumab Sensitive : C3	pertuzumab Sensitive: C3 – Early Trials pertuzumab Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3